Bacharier et al. [27] Zieger et al. [40] Bacharier et al. [35]
Number enrolled 238 278 607
Age (months) 12-59 12-53 12-71
Entry criteria
>2 clinically significant wheeze attacks >1 clinically significant wheeze attacks Positive API >2 clinically significant wheeze attacks
Duration (weeks) 52 52 52-78
Intervention
Intermittent ICS, or intermittent LTRA, vs. placebo during respiratory illnesses Daily ICS versus ICS only during respiratory illnesses Azithromycin vs. placebo during respiratory illnesses